Published in Proc Natl Acad Sci U S A on June 11, 2013
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
The revolution will not be crystallized: a new method sweeps through structural biology. Nature (2015) 1.85
Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat Struct Mol Biol (2013) 1.80
Single-Particle Cryo-EM at Crystallographic Resolution. Cell (2015) 1.74
Avoiding the pitfalls of single particle cryo-electron microscopy: Einstein from noise. Proc Natl Acad Sci U S A (2013) 1.64
A primer to single-particle cryo-electron microscopy. Cell (2015) 1.56
Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer. PLoS One (2015) 1.46
Structure of trimeric HIV-1 envelope glycoproteins. Proc Natl Acad Sci U S A (2013) 1.29
A functional interaction between gp41 and gp120 is observed for monomeric but not oligomeric, uncleaved HIV-1 Env gp140. J Virol (2013) 1.25
Finding trimeric HIV-1 envelope glycoproteins in random noise. Proc Natl Acad Sci U S A (2013) 1.21
New approaches to HIV vaccine development. Curr Opin Immunol (2015) 1.17
CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies. J Virol (2014) 1.12
Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist. Acc Chem Res (2014) 1.04
Reply to Subramaniam, van Heel, and Henderson: Validity of the cryo-electron microscopy structures of the HIV-1 envelope glycoprotein complex. Proc Natl Acad Sci U S A (2013) 0.99
Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action. Proteins (2014) 0.99
Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140. J Virol (2015) 0.97
Progress in HIV-1 vaccine development. J Allergy Clin Immunol (2014) 0.94
The Atomic Structure of the HIV-1 gp41 Transmembrane Domain and Its Connection to the Immunogenic Membrane-proximal External Region. J Biol Chem (2015) 0.94
Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope. J Virol (2014) 0.91
Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization. PLoS Pathog (2014) 0.90
Estimated secondary structure propensities within V1/V2 region of HIV gp120 are an important global antibody neutralization sensitivity determinant. PLoS One (2014) 0.86
HIV-1 envelope protein gp41: an NMR study of dodecyl phosphocholine embedded gp41 reveals a dynamic prefusion intermediate conformation. Structure (2014) 0.86
Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation. J Biol Chem (2014) 0.84
Complete dissociation of the HIV-1 gp41 ectodomain and membrane proximal regions upon phospholipid binding. J Biomol NMR (2015) 0.80
Herpesvirus gB: A Finely Tuned Fusion Machine. Viruses (2015) 0.80
Structures of viral membrane proteins by high-resolution cryoEM. Curr Opin Virol (2014) 0.80
Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops. Sci Rep (2014) 0.80
Morphology and ultrastructure of retrovirus particles. AIMS Biophys (2015) 0.79
HIV-1 envelope glycoprotein trimer immunogenicity elicited in the presence of human CD4 alters the neutralization profile. AIDS Res Hum Retroviruses (2014) 0.78
Recombinant expression, purification, and biophysical characterization of the transmembrane and membrane proximal domains of HIV-1 gp41. Protein Sci (2014) 0.77
Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1. Curr HIV Res (2013) 0.77
Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region. Virology (2015) 0.76
A Conserved Glycan in the C2 Domain of HIV-1 Envelope Acts as a Molecular Switch to Control X4 Utilization by Clonal Variants with Identical V3 Loops. PLoS One (2015) 0.76
Single-particle electron microscopy in the study of membrane protein structure. Microscopy (Oxf) (2015) 0.76
Biophysical Characterization of a Vaccine Candidate against HIV-1: The Transmembrane and Membrane Proximal Domains of HIV-1 gp41 as a Maltose Binding Protein Fusion. PLoS One (2015) 0.76
Particle alignment reliability in single particle electron cryomicroscopy: a general approach. Sci Rep (2016) 0.75
HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Microbiol Mol Biol Rev (2016) 0.75
Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. J Virol (2017) 0.75
A mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine development. PLoS One (2014) 0.75
Insights into the Conformation of the Membrane Proximal Regions Critical to the Trimerization of the HIV-1 gp41 Ectodomain Bound to Dodecyl Phosphocholine Micelles. PLoS One (2016) 0.75
Evaluation of the contribution of the transmembrane region to the ectodomain conformation of the human immunodeficiency virus (HIV-1) envelope glycoprotein. Virol J (2017) 0.75
Antigenic and 3D structural characterization of soluble X4 and hybrid X4-R5 HIV-1 Env trimers. Retrovirology (2014) 0.75
Validation of 3D EM Reconstructions: The Phantom in the Noise. AIMS Biophys (2015) 0.75
Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors. J Virol (2017) 0.75
Antigenic characterization of the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor incorporated into nanodiscs. PLoS One (2017) 0.75
Dissecting Virus Infectious Cycles by Cryo-Electron Microscopy. PLoS Pathog (2016) 0.75
Accurate predictions of population-level changes in sequence and structural properties of HIV-1 Env using a volatility-controlled diffusion model. PLoS Biol (2017) 0.75
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science (1984) 32.33
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69
Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature (1981) 24.17
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Atomic structure of the ectodomain from HIV-1 gp41. Nature (1997) 16.31
Core structure of gp41 from the HIV envelope glycoprotein. Cell (1997) 16.18
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science (1998) 12.52
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med (1991) 9.28
Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science (1985) 8.53
Structure of an unliganded simian immunodeficiency virus gp120 core. Nature (2005) 8.30
A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell (1993) 8.26
Molecular architecture of native HIV-1 gp120 trimers. Nature (2008) 8.04
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A (1997) 5.76
Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol (2000) 5.71
Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol (1998) 5.62
Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science (1985) 5.42
Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci U S A (2000) 4.44
Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science (2011) 4.30
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci U S A (2009) 3.92
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog (2012) 3.07
Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology (2005) 2.86
Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J Virol (2000) 2.86
Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci U S A (2012) 2.69
Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog (2010) 2.55
Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A (2004) 2.44
Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat Struct Mol Biol (2012) 2.36
Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog (2010) 2.33
Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol Cell (2010) 2.22
Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol (2003) 1.95
Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J Virol (2009) 1.88
Model for intracellular folding of the human immunodeficiency virus type 1 gp120. J Virol (1989) 1.70
Maturation of HIV envelope glycoprotein precursors by cellular endoproteases. Biochim Biophys Acta (2000) 1.70
Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker. J Virol (2006) 1.58
The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions. J Biol Chem (2002) 1.58
Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure. Proc Natl Acad Sci U S A (2010) 1.54
A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer. J Virol (2010) 1.43
Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop. J Virol (2010) 1.39
Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120. J Virol (2012) 1.21
Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. Biochemistry (2005) 1.20
The highly conserved layer-3 component of the HIV-1 gp120 inner domain is critical for CD4-required conformational transitions. J Virol (2012) 1.19
Proteolytic processing of the human immunodeficiency virus envelope glycoprotein precursor decreases conformational flexibility. J Virol (2012) 0.99
Alanine scanning mutagenesis of HIV-1 gp41 heptad repeat 1: insight into the gp120-gp41 interaction. Biochemistry (2010) 0.99
An alternative conformation of the gp41 heptad repeat 1 region coiled coil exists in the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor. Virology (2005) 0.95
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science (2007) 4.35
Comparative epidemiology of human infections with avian influenza A H7N9 and H5N1 viruses in China: a population-based study of laboratory-confirmed cases. Lancet (2013) 3.77
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res (2010) 3.16
Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell (2003) 3.03
Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol (2002) 2.81
Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure (2008) 2.74
Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci U S A (2012) 2.69
Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A (2004) 2.44
Hexagonal assembly of a restricting TRIM5alpha protein. Proc Natl Acad Sci U S A (2010) 2.40
Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat Struct Mol Biol (2012) 2.36
Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog (2009) 2.34
Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication. J Virol (2008) 2.30
Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology (2003) 2.25
Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol Cell (2010) 2.22
Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J Virol (2007) 2.19
Structural basis of J cochaperone binding and regulation of Hsp70. Mol Cell (2007) 2.14
Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology (2011) 2.13
HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase. PLoS Pathog (2007) 2.13
Structure of the Hsp110:Hsc70 nucleotide exchange machine. Mol Cell (2008) 1.96
Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J Virol (2013) 1.93
Spatial analysis of malaria in Anhui province, China. Malar J (2008) 1.92
Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. Virology (2003) 1.90
Type-2 cells as link between glial and neuronal lineage in adult hippocampal neurogenesis. Glia (2006) 1.90
Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res (2010) 1.78
Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. Breast Cancer Res Treat (2012) 1.71
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem (2008) 1.66
Analysis of αSMA-labeled progenitor cell commitment identifies notch signaling as an important pathway in fracture healing. J Bone Miner Res (2014) 1.66
Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem (2005) 1.65
Oil and tocopherol content and composition of pumpkin seed oil in 12 cultivars. J Agric Food Chem (2007) 1.65
Modulation of retroviral restriction and proteasome inhibitor-resistant turnover by changes in the TRIM5alpha B-box 2 domain. J Virol (2007) 1.60
High-affinity peptide against MT1-MMP for in vivo tumor imaging. J Control Release (2011) 1.59
SMM-chemokines: a class of unnatural synthetic molecules as chemical probes of chemokine receptor biology and leads for therapeutic development. Chem Biol (2006) 1.58
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1. J Virol (2004) 1.51
Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc Natl Acad Sci U S A (2010) 1.51
Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: analysis of 2,269 Chinese breast cancer patients treated with extended radical mastectomy. Breast Cancer Res Treat (2007) 1.49
Generation of kinins during preparation and storage of whole blood-derived platelet concentrates. Transfusion (2007) 1.49
Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity. PLoS Pathog (2011) 1.47
In vivo fate mapping identifies mesenchymal progenitor cells. Stem Cells (2012) 1.44
A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer. J Virol (2010) 1.43
Improving the performance of outbreak detection algorithms by classifying the levels of disease incidence. PLoS One (2013) 1.36
Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J Virol (2004) 1.35
Osterix-cre labeled progenitor cells contribute to the formation and maintenance of the bone marrow stroma. PLoS One (2013) 1.34
Diversity and abundance of oil-degrading bacteria and alkane hydroxylase (alkB) genes in the subtropical seawater of Xiamen Island. Microb Ecol (2010) 1.33
Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines. J Biol Chem (2002) 1.33
Genetic control of floral zygomorphy in pea (Pisum sativum L.). Proc Natl Acad Sci U S A (2008) 1.27
Crystallization of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr (2006) 1.23
Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain. J Virol (2009) 1.23
Emergence of a tetracycline-resistant Campylobacter jejuni clone associated with outbreaks of ovine abortion in the United States. J Clin Microbiol (2008) 1.23
Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology (2009) 1.20
Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorg Med Chem Lett (2005) 1.20
High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection. J Virol (2011) 1.19
Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody. J Virol (2005) 1.19
The highly conserved layer-3 component of the HIV-1 gp120 inner domain is critical for CD4-required conformational transitions. J Virol (2012) 1.19
NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One (2011) 1.19
Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1alpha on CXCR4 transmembrane helical domains. J Virol (2005) 1.18
Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors. J Med Chem (2007) 1.17
Human exposure to live poultry and psychological and behavioral responses to influenza A(H7N9), China. Emerg Infect Dis (2014) 1.17
Aggressive angiomyxoma: an unusual presentation. Korean J Radiol (2011) 1.16
Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors. J Virol (2005) 1.14
Strontium enhances osteogenic differentiation of mesenchymal stem cells and in vivo bone formation by activating Wnt/catenin signaling. Stem Cells (2011) 1.13
Long bone fracture repair in mice harboring GFP reporters for cells within the osteoblastic lineage. J Orthop Res (2010) 1.11
CDK5 is essential for TGF-β1-induced epithelial-mesenchymal transition and breast cancer progression. Sci Rep (2013) 1.11
Role of CD4 receptor down-regulation during HIV-1 infection. Curr HIV Res (2004) 1.10
Functional interplay between the B-box 2 and the B30.2(SPRY) domains of TRIM5alpha. Virology (2007) 1.09
Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma. Bioorg Med Chem Lett (2005) 1.08
Isolation and preliminary probiotic selection of lactobacilli from koumiss in Inner Mongolia. J Basic Microbiol (2009) 1.06
Identification of a human immunodeficiency virus type 1 envelope glycoprotein variant resistant to cold inactivation. J Virol (2009) 1.05
Post-junctional facilitation of Substance P signaling in a tibia fracture rat model of complex regional pain syndrome type I. Pain (2009) 1.05
Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. J Biol Chem (2005) 1.05
Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proc Natl Acad Sci U S A (2013) 1.05
Allosteric inhibition of human immunodeficiency virus integrase: late block during viral replication and abnormal multimerization involving specific protein domains. J Biol Chem (2014) 1.04
Thermomechanics of nanocrystalline nickel under high pressure-temperature conditions. Nano Lett (2007) 1.02
Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2. Bioorg Med Chem Lett (2006) 1.02
Severe acute pancreatitis in China: etiology and mortality in 1976 patients. Pancreas (2007) 1.01
Toward low friction in high vacuum for hydrogenated diamondlike carbon by tailoring sliding interface. ACS Appl Mater Interfaces (2013) 1.01
The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer. Oncotarget (2014) 1.01
Neuroprotective role of bradykinin because of the attenuation of pro-inflammatory cytokine release from activated microglia. J Neurochem (2007) 1.01
Phylogenetic diversity of the Bacillus pumilus group and the marine ecotype revealed by multilocus sequence analysis. PLoS One (2013) 1.00
Acupuncture for dysphagia in acute stroke. Cochrane Database Syst Rev (2008) 1.00
Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation. Cancer Res (2013) 1.00
Reply to Subramaniam, van Heel, and Henderson: Validity of the cryo-electron microscopy structures of the HIV-1 envelope glycoprotein complex. Proc Natl Acad Sci U S A (2013) 0.99